Evan J Zasowski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3638331/publications.pdf

Version: 2024-02-01

32	1,309	16	30
papers	citations	h-index	g-index
33	33	33	1743
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Multicenter Cohort Study of Ceftaroline Versus Daptomycin for Treatment of Methicillin-Resistant <i>Staphylococcus aureus </i> Bloodstream Infection. Open Forum Infectious Diseases, 2022, 9, ofab606.	0.9	12
2	Standardized Treatment and Assessment Pathway Improves Mortality in Adults With Methicillin-resistant <i>Staphylococcus aureus</i> Bacteremia: STAPH Study. Open Forum Infectious Diseases, 2021, 8, ofab261.	0.9	7
3	Daptomycin Plus \hat{I}^2 -Lactam Combination Therapy for Methicillin-resistant Staphylococcus aureus Bloodstream Infections: A Retrospective, Comparative Cohort Study. Clinical Infectious Diseases, 2020, 71, 1-10.	5.8	79
4	Systematic review of the impact of appropriate versus inappropriate initial antibiotic therapy on outcomes of patients with severe bacterial infections. International Journal of Antimicrobial Agents, 2020, 56, 106184.	2.5	48
5	Evaluation of the INCREMENT-CPE, Pitt Bacteremia and qPitt Scores in Patients with Carbapenem-Resistant Enterobacteriaceae Infections Treated with Ceftazidime–Avibactam. Infectious Diseases and Therapy, 2020, 9, 291-304.	4.0	12
6	Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	43
7	Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia. International Journal of Antimicrobial Agents, 2019, 54, 346-350.	2.5	9
8	Relationship Status between Vancomycin Loading Dose and Treatment Failure in Patients with MRSA Bacteremia: It's Complicated. Infectious Diseases and Therapy, 2019, 8, 627-640.	4.0	11
9	Withdrawn as Duplicate: The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections Treated With Vancomycin. Open Forum Infectious Diseases, 2019, 6, ofz077.	0.9	8
10	Reply to Cheng and Chuang. Clinical Infectious Diseases, 2019, 69, 903-904.	5.8	1
11	The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections Treated With Vancomycin. Open Forum Infectious Diseases, 2019, 6, ofz079.	0.9	10
12	Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections. Open Forum Infectious Diseases, 2019, 6, ofz522.	0.9	85
13	Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint. Clinical Infectious Diseases, 2019, 68, 1650-1657.	5.8	42
14	Risk Factors for Bloodstream Infections Among an Urban Population with Skin and Soft Tissue Infections: A Retrospective Unmatched Case-Control Study. Infectious Diseases and Therapy, 2019, 8, 75-85.	4.0	2
15	Role of Vancomycin Minimum Inhibitory Concentrations by Modified Population Analysis Profile Method and Clinical Outcomes in High Inoculum Methicillin-Resistant Staphylococcus aureus Infections. Infectious Diseases and Therapy, 2018, 7, 161-169.	4.0	7
16	Novel application of published risk factors for methicillin-resistant S. aureus in acute bacterial skin and skin structure infections. International Journal of Antimicrobial Agents, 2018, 51, 43-46.	2.5	10
17	Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous Vancomycin. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	96
18	Antimicrobial Stewardship Opportunities in Critically Ill Patients with Gram-Negative Lower Respiratory Tract Infections: A Multicenter Cross-Sectional Analysis. Infectious Diseases and Therapy, 2018, 7, 135-146.	4.0	14

#	Article	IF	Citations
19	2379. Multicenter Evaluation of Ceftazidime–Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections. Open Forum Infectious Diseases, 2018, 5, S708-S709.	0.9	O
20	2384. Multidrug-Resistant Gram-Negative Infections Treated With Ceftolozane–Tazobactam: Impact of Delayed Initiation. Open Forum Infectious Diseases, 2018, 5, S710-S711.	0.9	0
21	Multicenter Observational Study of Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	60
22	Multidrug-resistant Pseudomonas aeruginosa lower respiratory tract infections in the intensive care unit: Prevalence and risk factors. Diagnostic Microbiology and Infectious Disease, 2017, 89, 61-66.	1.8	28
23	A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	178
24	Comparison of clinical outcomes and risk factors in polymicrobial versus monomicrobial enterococcal bloodstream infections. American Journal of Infection Control, 2016, 44, 917-921.	2.3	9
25	Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections. Antimicrobial Agents and Chemotherapy, 2016, 60, 5841-5848.	3.2	58
26	Characterization of the haematological profile of 21 days of tedizolid in healthy subjects. Journal of Antimicrobial Chemotherapy, 2016, 71, 2553-2558.	3.0	39
27	Comparison of outcomes between patients with single versus multiple positive blood cultures for Enterococcus: Infection versus illusion?. American Journal of Infection Control, 2016, 44, 47-49.	2.3	5
28	Time Is of the Essence: The Impact of Delayed Antibiotic Therapy on Patient Outcomes in Hospital-Onset Enterococcal Bloodstream Infections. Clinical Infectious Diseases, 2016, 62, 1242-1250.	5.8	99
29	The βâ€Lactams Strike Back: Ceftazidimeâ€Avibactam. Pharmacotherapy, 2015, 35, 755-770.	2.6	160
30	Identification of optimal renal dosage adjustments for high-dose extended-infusion cefepime dosing regimens in hospitalized patients. Journal of Antimicrobial Chemotherapy, 2015, 70, 877-881.	3.0	17
31	Vancomycin Exposure in Patients With Methicillin-Resistant Staphylococcus aureus Bloodstream Infections: How Much Is Enough?. Clinical Infectious Diseases, 2014, 59, 666-675.	5.8	139
32	Relationship between Time to Clinical Response and Outcomes among Pneumonia Outcomes Research Team (PORT) Risk Class III and IV Hospitalized Patients with Community-Acquired Pneumonia Who Received Ceftriaxone and Azithromycin. Antimicrobial Agents and Chemotherapy, 2014, 58, 3804-3813.	3.2	21